Tony Philip, MD, FACP, FASCO

We're seeking a Life Sciences Contracts Attorney to help us accelerate chordoma therapy development. If you're an experienced attorney who'd enjoy being embedded within a patient-driven research and drug development organization (or if you know others who may be interested), please apply or spread the word! Details: lnkd.in/gEpTn8-t

Basket trial of the EZH2 inhibitor tazemetostat demonstrated preliminary antitumor activity with responses in rhabdoid tumors, INI1-negative tumors and poorly differentiated chordomas. No responses seen in synovial sarcoma and renal medullary carcinoma. nature.com/articles/s4146…

Gloria Marquina invites you to the CTOS Spring Webinar 2026! Details and registration: ctos.org/EducationalPro…

Ipsen announced the voluntary withdrawal of tazemetostat from all global markets and for all indications, effective immediately. This decision follows a recommendation from the IDMC based on emerging safety data from the phase 1b/3 SYMPHONY-1 trial. hubs.li/Q046fY7l0

When patients, caregivers, and physicians speak, we listen. Their voices remind us why this matters — and why action can’t wait. Sign & share the petition today: brigimadlinpetition.org #SaveBrigimadlin #PatientVoices #liposarcoma @Boehringer

#brigimadlin held real hope for patients with dedifferentiated liposarcoma. Sign & share the petition to help the research begin again. brigimadlinpetition.org #SaveBrigimadlin #PatientVoices #liposarcoma @Boehringer

Serious drug-shortage issue for ifosfamide expected over the next few months due to manufacturing problems. This can have a major impact on the curative treatment of adult and paediatric patients with soft tissue sarcomas and Ewing family of tumours

ASCO GI is upon us. The data leakage has begun 👀🔥 Late-breaking press release ahead of ASCO GI for HERIZON-GEA-01, testing zanidatamab + chemo, with or without tislelizumab, vs trastuzumab + chemo in first-line HER2+ locally advanced or metastatic GEA. Important caveat up front: this is a press release, not a paper. But the signal is hard to ignore. 🧬 PFS improved in both zanidatamab arms Median PFS 12.4 months for both doublet and triplet vs 8.1 months with trastuzumab Roughly a 35% reduction in risk of progression 🧠 The real interest lies in OS Triplet median OS 26.4 months vs 19.2 months with trastuzumab That’s more than two years median OS in metastatic GEA The doublet also crossed 24 months with a strong trend (is tisle necessary?) 🧐 Key nuance: PFS is essentially identical between doublet and triplet OS clearly separates This looks like depth and durability rather than early disease control 📊 ORR is similar across arms, but duration of response is dramatically longer DoR 20.7 months with the triplet vs 8.3 months with trastuzumab 💧 Toxicity note Diarrhea is the standout issue and will need proactive management Grade 3 or higher diarrhea occurred in roughly 20 to 25 percent, with overall diarrhea rates around 40 percent Open question I would love to see this compared head-to-head against current SoC chemo + trastuzumab + pembrolizumab. That said, it’s hard to argue with a two-year median OS and a clear survival tail. Takeaway: If confirmed on full presentation, zanidatamab looks poised to replace trastuzumab in first-line HER2+ GEA. The next step may not be whether it works, but how much intensity each patient really needs. #GI26 @OncoAlert @TheGutOncLab investor.jazzpharma.com/news-releases/…

Recently, just before starting lifesaving treatment, @AnthemBCBS and @CarelonRx denied immunotherapy for a patient with advanced cancer who is MSI-H and ctDNA-positive—meaning their recurrence risk is extreme. FOLFOX is not an option due to severe neuropathy. Single-agent 5-FU is harmful in this disease subtype. Immunotherapy is the only rational treatment based on NCCN guidelines and phase III published data (ATOMIC). During the peer-to-peer review, the reviewer said: I do not have the authority to approve this based on my guidelines no matter what you say. This is not medicine. This is not quality control. This is insurance blocking evidence-based care in a curative setting. Patients deserve better.

The whole medical publishing ecosystem (free content, free peer review, but $$ to publish/read) is a bizarre, exploitative business model. Even if one believes clinicians owe some degree of unpaid "academic service," it’s absurd publishers profit so massively off our free labor.

In 2024, Elsevier publishers, parent company of @sciencedirect reported profits of over 3 Billion pounds and @SpringerNature reported over 1.8 billion pounds of profit. All off the work we do for them for free. Hey publishers, pay for reviews.

Back home from #CTOS2025, but I want to remind people that the @SarcomaAlliance will reimburse expenses up to $1,000 for patients who travel to get a second opinion from a sarcoma specialist. sarcomaalliance.org/second-opinion…

@YJanjigianMD @CentralParkWMD @DrSDNimer @MSK_DeptOfMed @MarcHilmi @nasca_vincenzo @CpcrMsk @MSKCancerCenter Congratulations Yelena ! A big year for major accomplishments.

@CentralParkWMD @DrSDNimer @MSK_DeptOfMed @MarcHilmi @nasca_vincenzo @CpcrMsk @MSKCancerCenter Overwhelmed with gratitude and love from my colleagues, mentees and @MSKCancerCenter

Practice-changing contributions and a beautiful narrative of a career dedicated to advancing oncology #GastricCancer #EsophagealCancer Congrats 🎉 to @YJanjigianMD 🪑#Endowment Full circle. Her journey began with @DrSDNimer 🌟#GIOnc #Leadership #sPARKLab 💜 @MSK_DeptOfMed

@SuzieSiegel Happy Birthday !

I am 67 today. My great thanks to the sarcoma doctors and scientists who make birthdays possible. #ctos2025

@allisonoconn @dgermain21 Interestingly, in GI it tends to be given over 30 min but in sarcoma it is more likely to be given at fixed dose rate 10mg/m2/min but likely varies by institutions There’s also the rare gem induced TTP

@dgermain21 This is a good question!! I was taught in in the context of GI where we want to avoid cytopenias so I’m not sure!

Today I learned that the rate of gemcitabine infusion is correlated with degree of cytopenias, with slower infusion causing more cytopenias.

Patients like Ann need treatment options. Sign the petition: brigimadlinpetition.org, share, and tag @Boehringer #SaveBrigimadlin #Liposarcoma #PatientVoices

.@RobinL_Jones @royalmarsden presenting ChonDRAgon PhII registrational study of Ozekibart in conventional #chondrosarcoma #CTOS2025 - No approved systemic therapies - mPFS 5.5 mo, with 21.7% w/o prog @ 12 mo - Activity in both IDH-WT & mut - TRAE incl ~13% fatigue, ~6% hepatitis

@RLRandallMD @WTapMD @SilviaStacchia @stern_sydney @UCD_Cancer @UCDavisHealth @UCDavisOrtho @UCDavisMed @ASCO @aoa1887 @AAOS1 @TGCTSupportorg @Liferaftgroup @SarcomaAlliance @CureSarcoma @sarcomacancerca Comprehensive and thorough presentation by everyone

Super honored to hang with @WTapMD, @SilviaStacchia & @stern_sydney on the global stage to discuss MDT mx of #TGCT. @UCD_Cancer @UCDavisHealth @UCDavisOrtho @UCDavisMed @ASCO @aoa1887 @AAOS1 @TGCTSupportorg @Liferaftgroup @SarcomaAlliance @CureSarcoma @sarcomacancerca

Sarah’s story shows what’s possible: Brigimadlin helped her more than any other treatment. Let’s make sure every patient can access this life-changing option. Sign the petition: brigimadlinpetition.org @Boehringer #SaveBrigimadlin #SignThePetition #liposarcoma

#CTOS2025 is not only about great science, it's also a perfect opportunity for mentorship for trainees and young fellows! Don't miss the 🌅 Sunrise Mentorship Session on Nov 13, 7.00 am ( breakfast and coffee will be served ☕)! Check topics and mentors 🧑‍🏫on the graphic⬇️